NASDAQ:QNRX Quoin Pharmaceuticals Q1 2025 Earnings Report $8.98 +0.40 (+4.66%) Closing price 06/24/2025 03:59 PM EasternExtended Trading$8.64 -0.35 (-3.84%) As of 09:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings History Quoin Pharmaceuticals EPS ResultsActual EPS-$6.50Consensus EPS -$3.85Beat/MissMissed by -$2.65One Year Ago EPSN/AQuoin Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AQuoin Pharmaceuticals Announcement DetailsQuarterQ1 2025Date5/13/2025TimeBefore Market OpensConference Call DateTuesday, May 13, 2025Conference Call Time9:30AM ETUpcoming EarningsQuoin Pharmaceuticals' Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Tuesday, August 12, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Quoin Pharmaceuticals Earnings HeadlinesQuoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton SyndromeJune 24 at 5:28 PM | tmcnet.comQuoin Pharmaceuticals, Ltd. (QNRX) - Yahoo FinanceJune 24 at 5:28 PM | finance.yahoo.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.June 25, 2025 | Porter & Company (Ad)QNRX: With FDA Clearance to Initiate 2nd NS Whole Body Study for QRX003, Clinical Activities Expand FurtherMay 29, 2025 | finance.yahoo.comQuoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton SyndromeMay 20, 2025 | globenewswire.comQuoin reports progress in pediatric skin disorder studyMay 15, 2025 | investing.comSee More Quoin Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Quoin Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quoin Pharmaceuticals and other key companies, straight to your email. Email Address About Quoin PharmaceuticalsQuoin Pharmaceuticals (NASDAQ:QNRX), Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.View Quoin Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings NIKE (6/26/2025)Bank of America (7/14/2025)Interactive Brokers Group (7/15/2025)America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
